|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
EPO2006-AISSM04 2006-006482-16, NCT00804050
|
|
|
|
|
|
|
|
Last Modified: 1/15/2008  First Published: 2/21/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
NU-05M1 NU-0310-093, SPRI-NU-05M1, NCT00301067
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
NCI, Other
|
|
|
|
UMCC 2008.042 HUM%21242, NCT00794547
|
|
|
|
|
|
|
|
Last Modified: 10/23/2008  First Published: 5/28/2004 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
RPCI-RP-0212 NCT00084864
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
No age specified
|
|
|
|
Other
|
|
|
|
FD-R-2025-01 FD-R-002025-01, NCT00030069
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Supportive care, Treatment
|
|
|
|
Approved-not yet active
|
|
|
|
18 to 75
|
|
|
|
Other
|
|
|
|
004253 NCT00445250
|
|
|
|
|
|
|
|
Last Modified: 8/27/2008  First Published: 6/3/2008 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Biomarker/Laboratory analysis, Prevention
|
|
|
|
Active
|
|
|
|
40 to 79
|
|
|
|
NCI
|
|
|
|
RPCI-I-90206 I 90205, NCT00690924
|
|
|
|